With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 ...

Filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF), and sargramostim, a recombinant granulocytemacrophage colony-stimulating factor (GM-CSF), have been available in the United ...

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

Niopeg is a long-acting form of recombinant human granulocyte colony-stimulating factor or filgrastim. It is specifically indicated to decrease the incidence of infection, as manifested by febrile ...